Non-invasive protein biomarkers use blood, CSF, or other accessible fluids to detect and monitor disease without surgical biopsies. To be clinically useful, these tests must measure very low-abundance proteins with high specificity, support longitudinal monitoring, and scale across labs, which places tight performance demands on every part of the immunoassay.
Interest in fluid biomarkers has grown rapidly as clinicians seek earlier, less invasive diagnostic options for oncology and neurodegeneration. Presymptomatic Alzheimer’s studies now use blood-based protein panels combined with imaging or cognitive endpoints to detect disease before symptoms appear. In parallel, wellness-oriented panels measure inflammatory and metabolic proteins to flag cardiometabolic risk in routine checkups.
The core challenge is not simply finding a biomarker candidate, but building an assay that delivers trustworthy numbers in real-world samples. Many disease-relevant proteins appear at higher concentrations in cerebrospinal fluid than in blood, but blood is easier to collect at scale. That means assays for blood-based biomarkers must be substantially more sensitive while still rejecting background noise from abundant serum proteins.
Sample matrix selection for non-invasive biomarker assays balances access (how easy it is to obtain the sample) against signal quality (how abundant and stable the target protein is). CSF typically provides higher biomarker concentrations and clearer CNS-derived signatures, while blood supports scalable, repeatable testing but requires much higher assay sensitivity.
Many neurodegeneration biomarkers, including amyloid‑beta, tau, neurofilament light chain, and progranulin, are orders of magnitude more concentrated in CSF than in plasma or serum. This makes CSF ideal for early-stage discovery work, analytical method development, and initial clinical validation where the priority is demonstrating that a protein track disease burden or response to therapy. For example, multiplex CSF panels have been used to distinguish Alzheimer’s disease from other dementias when MRI or clinical symptoms are ambiguous.
Blood-based testing, by contrast, is more attractive for longitudinal monitoring and large, geographically diverse trials. A simple venipuncture can be integrated into standard care visits, which is one reason the U.S. FDA’s first cleared blood test to aid in Alzheimer’s diagnosis was widely covered in 2025 (FDA). But moving from CSF to blood is not a one-to-one translation: matrix effects, protease activity, and non-specific binding all change.
For assay developers, a practical strategy is to start by proving analytical performance in CSF, where signal-to-noise is more favorable, then incrementally adapt to serum or plasma. This often involves tightening antibody selection criteria, optimizing blocking buffers, and revalidating key metrics such as lower limit of detection (LOD), linearity, and parallelism across matrices.
High-affinity antibodies are essential for non-invasive biomarker assays because they determine how low you can go in concentration while still distinguishing true signal from noise. When target proteins are present at picogram-per-milliliter levels in blood, even modest cross-reactivity or lot-to-lot variability can completely erase clinically relevant differences.
Affinity, expressed as a dissociation constant (KD), directly impacts both sensitivity and dynamic range. In ultrasensitive digital ELISA formats, sub‑nanomolar or picomolar KD values are often required to bind rare target molecules efficiently during short incubation times. At the same time, non-specific binding must be minimized so that the background signal remains stable across patient cohorts and sample types. For multi-marker panels, cross-reactivity with structurally related proteins can confound interpretation and inflate false positives.
Equally important is reproducible performance across antibody lots, instruments, and sites. Poorly characterized antibodies may appear to work during early research use, only to fail during multi-site clinical validation because epitope recognition, glycosylation sensitivity, or stability under shipping conditions were not fully understood. Independent consortia have repeatedly shown that a significant fraction of commercial antibodies do not recognize their advertised targets without extensive validation in the relevant application.
By contrast, recombinant antibody platforms support sequence-defined, lot-consistent reagents. When combined with surface plasmon resonance (SPR)-based kinetic characterization and orthogonal specificity testing, developers can rank hundreds of candidates on attributes that matter directly for diagnostic reliability: on-rate and off-rate, epitope diversity, stability in serum or CSF, and performance in sandwich formats.
Recombinant antibody workflows for progranulin show how a structured, data-rich approach can turn a challenging protein target into a robust immunoassay suitable for clinical samples. Progranulin is a secreted glycoprotein implicated in tissue repair, lysosomal function, and neuroprotection; reduced levels are strongly associated with GRN mutation–driven frontotemporal dementia and are being investigated as a biomarker in other neurodegenerative diseases.
In a typical end-to-end workflow, development begins with intelligent antigen design rather than simply expressing the full-length protein and hoping for useful epitopes. Structural predictions from tools such as AlphaFold are combined with proprietary antigenicity scoring to rank fragments based on epitope exposure, predicted disorder, and solvent accessibility. This increases the odds that immunization will produce antibodies against functionally relevant, accessible regions of progranulin.
Rabbits are commonly selected as the host species to take advantage of robust in vivo affinity maturation. Antigen-positive B cells are then isolated using multi-color FACS, and their variable regions are cloned into recombinant IgG expression backbones. A plasmid-free expression system, such as transient expression in HEK293 cells, supports rapid production of hundreds of full-length antibodies for early screening.
High-throughput SPR analysis on a platform like the Carterra LSA enables parallel measurement of kinetic constants and specificity to both the recombinant antigen and full-length progranulin. Epitope binning and community plots reveal clusters of antibodies that recognize distinct regions of the protein. From here, a short list of capture–detection pair candidates with complementary epitopes and favorable kinetics is chosen for functional testing.
Multiplex protein biomarker panels provide richer clinical information than single-marker tests by capturing multiple pathways involved in disease onset and progression. For progranulin, that could mean measuring it alongside inflammatory cytokines, lysosomal markers, and neurodegeneration proteins to distinguish overlapping clinical phenotypes and refine prognosis.
In oncology, blood-based tests under development already combine protein panels with cfDNA mutation profiling to improve early cancer detection. One example, CancerSEEK, evaluates eight circulating proteins together with tumor-specific DNA variants to detect multiple cancer types from a single blood draw (J Transl Med). Similar logic applies in neurology, where panels incorporating amyloid‑beta, tau, neurofilament light chain, and emerging candidates such as progranulin can stratify patients more accurately than any single analyte alone.
For assay developers, designing a progranulin immunoassay that is multiplex-ready means validating it across a broader dynamic range, stress-testing it against potential interferents, and confirming that epitopes remain accessible in the presence of other capture antibodies. It also requires evaluating cross-platform transferability so that the same antibody pair can function in standalone ELISA, bead-based multiplex, or digital immunoassay formats.
A practical example is our optimization of a chemiluminescent ELISA for progranulin, where analytical sensitivity reached an LOD of approximately 14 pg/mL in human CSF and serum. In that configuration, progranulin levels could be reliably detected in both disease and control samples, with clear separation of average signals in serum. Those performance metrics are sufficient not just for proof-of-concept studies but also for integration into multi-marker panels in translational cohorts.
Strategic partnerships between assay developers, diagnostic companies, and antibody specialists are increasingly important for turning non-invasive biomarker concepts into validated clinical tests. Internal R&D teams may have deep disease biology expertise but limited bandwidth to engineer and characterize hundreds of antibody candidates per target under compressed timelines.
Working with a partner that offers an end-to-end recombinant antibody platform can compress the path from antigen concept to assay-ready antibody pairs. For example, a workflow that integrates AI-informed antigen design, rabbit immunization, high-throughput SPR screening, and systematic epitope binning can identify a lead progranulin antibody pair plus backups more rapidly. When those antibodies are then tested in disease-relevant matrices such as human CSF and serum, the resulting data package supports faster risk assessment for diagnostic programs.
Beyond discovery, partners who understand diagnostic regulatory expectations can help structure analytical validation studies for non-invasive biomarker assays—covering precision, accuracy, interference, stability, and lot-to-lot reproducibility. Having sequence-defined recombinant antibodies simplifies lot bridging and global manufacturing planning, both critical for scalable blood- or CSF-based tests.
For teams exploring progranulin or other emerging biomarkers, collaborating early in the project can surface design constraints before they become roadblocks. That might mean jointly prioritizing epitopes to avoid known polymorphisms, selecting formats that will transition cleanly to multiplex platforms, or building in redundancy so that panel performance is resilient to future assay improvements or regulatory changes. Aviva offer these services and would love to discuss a partnership!
You can read about our development of a high-sensitivity progranulin assay in the case study below, and contact us at info@avivasysbio.com to set up a discovery call.